IDEAYA Biosciences (IDYA) Total Current Liabilities (2018 - 2026)

IDEAYA Biosciences (IDYA) has 9 years of Total Current Liabilities data on file, last reported at $64.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 27.5% year-over-year to $64.8 million; the trailing twelve-month figure through Mar 2026 stood at $64.8 million (up 27.5% YoY), and the FY2025 full-year result was $58.8 million, up 27.66% from the prior year.
• Total Current Liabilities improved to $64.8 million in Q1 2026, from $58.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $64.8 million in Q1 2026 to a low of $24.9 million in Q3 2023.
• A 5-year average of $43.1 million and a median of $40.7 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities slumped 56.38% in 2023 and jumped 103.71% in 2025, its largest moves.
• Tracing IDYA's Total Current Liabilities over 5 years: stood at $31.7 million in 2022, then decreased by 14.56% to $27.1 million in 2023, then jumped by 70.0% to $46.1 million in 2024, then gained by 27.66% to $58.8 million in 2025, then advanced by 10.23% to $64.8 million in 2026.
• Business Quant data shows IDYA's Total Current Liabilities at $64.8 million in Q1 2026, $58.8 million in Q4 2025, and $64.5 million in Q3 2025.